CN111278990A - 评估抗癫痫药物拉莫三嗪引发皮肤药物不良反应风险的方法、其检测试剂和其用途 - Google Patents
评估抗癫痫药物拉莫三嗪引发皮肤药物不良反应风险的方法、其检测试剂和其用途 Download PDFInfo
- Publication number
- CN111278990A CN111278990A CN201780096270.9A CN201780096270A CN111278990A CN 111278990 A CN111278990 A CN 111278990A CN 201780096270 A CN201780096270 A CN 201780096270A CN 111278990 A CN111278990 A CN 111278990A
- Authority
- CN
- China
- Prior art keywords
- hla
- drug
- lamotrigine
- adverse
- alleles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001848 lamotrigine Drugs 0.000 title claims abstract description 40
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 229940079593 drug Drugs 0.000 title claims abstract description 27
- 239000001961 anticonvulsive agent Substances 0.000 title claims abstract description 23
- 206010067484 Adverse reaction Diseases 0.000 title claims abstract description 20
- 230000006838 adverse reaction Effects 0.000 title claims abstract description 20
- 229960003965 antiepileptics Drugs 0.000 title claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000001514 detection method Methods 0.000 title claims abstract description 8
- 208000019872 Drug Eruptions Diseases 0.000 claims abstract description 45
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims abstract description 36
- 108700028369 Alleles Proteins 0.000 claims abstract description 32
- 208000032678 Fixed drug eruption Diseases 0.000 claims abstract description 26
- 208000012587 fixed pigmented erythema Diseases 0.000 claims abstract description 26
- 206010061623 Adverse drug reaction Diseases 0.000 claims abstract description 23
- 230000009885 systemic effect Effects 0.000 claims abstract description 21
- 208000024891 symptom Diseases 0.000 claims abstract description 19
- 206010014950 Eosinophilia Diseases 0.000 claims abstract description 17
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims abstract description 14
- 231100000331 toxic Toxicity 0.000 claims abstract description 13
- 230000002588 toxic effect Effects 0.000 claims abstract description 13
- 206010037844 rash Diseases 0.000 claims abstract description 6
- 206010037868 Rash maculo-papular Diseases 0.000 claims abstract description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 230000002411 adverse Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000003556 anti-epileptic effect Effects 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010059284 Epidermal necrosis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 206010024570 Lip swelling Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- -1 SCAR Chemical compound 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004057 allelic distribution Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种评估抗癫痫药物拉莫三嗪(Lamotrigine)引发皮肤药物不良反应(Cutaneous Adverse Drug Reactions,CADRs)风险的方法，其中皮肤药物不良反应包括但不限于：斑丘疹(maculopapular eruption,MPE)、固定型药疹(fixed drug eruption,FDE)、史帝文生－琼森综合症(Stevens Johnson Syndrome,SJS)、毒性表皮坏死症(toxic epidermal necrolysis,TEN)、药疹伴以嗜酸粒细胞增多和全身症状(drug rash with eosinophilia and systemic symptoms,DRESS)。还提供一种用于评估患者发展出抗癫痫药物拉莫三嗪引发皮肤药物不良反应风险的检测试剂，包括测定特定HLA等位基因的试剂和其用途。
Description
PCT国内申请，说明书已公开。
Claims (9)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/107933 WO2019080077A1 (zh) | 2017-10-27 | 2017-10-27 | 评估抗癫痫药物拉莫三嗪引发皮肤药物不良反应风险的方法、其检测试剂和其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111278990A true CN111278990A (zh) | 2020-06-12 |
Family
ID=66247078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780096270.9A Pending CN111278990A (zh) | 2017-10-27 | 2017-10-27 | 评估抗癫痫药物拉莫三嗪引发皮肤药物不良反应风险的方法、其检测试剂和其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200318189A1 (zh) |
| JP (2) | JP2021500083A (zh) |
| KR (1) | KR20200077555A (zh) |
| CN (1) | CN111278990A (zh) |
| SG (1) | SG11202003391XA (zh) |
| WO (1) | WO2019080077A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588162A (zh) * | 2022-03-30 | 2022-06-07 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012741A1 (en) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| CN1902328A (zh) * | 2003-11-10 | 2007-01-24 | 中央研究院 | 用于药物不良反应的危险率评估 |
| US20120329045A1 (en) * | 2011-06-23 | 2012-12-27 | Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN105963311A (zh) * | 2016-07-13 | 2016-09-28 | 欧阳冬生 | 人参皂苷c-k与拉莫三嗪的组合物在制备抗癫痫药物中的应用 |
| CN106191300A (zh) * | 2016-09-22 | 2016-12-07 | 中南大学湘雅三医院 | 预测儿童患者严重药物性皮肤不良反应的生物标志物及应用 |
-
2017
- 2017-10-27 KR KR1020207014822A patent/KR20200077555A/ko not_active Application Discontinuation
- 2017-10-27 CN CN201780096270.9A patent/CN111278990A/zh active Pending
- 2017-10-27 SG SG11202003391XA patent/SG11202003391XA/en unknown
- 2017-10-27 US US16/759,151 patent/US20200318189A1/en not_active Abandoned
- 2017-10-27 WO PCT/CN2017/107933 patent/WO2019080077A1/zh active Application Filing
- 2017-10-27 JP JP2020543661A patent/JP2021500083A/ja active Pending
-
2022
- 2022-03-24 JP JP2022048589A patent/JP2022084843A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012741A1 (en) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| CN1902328A (zh) * | 2003-11-10 | 2007-01-24 | 中央研究院 | 用于药物不良反应的危险率评估 |
| US20120329045A1 (en) * | 2011-06-23 | 2012-12-27 | Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN105963311A (zh) * | 2016-07-13 | 2016-09-28 | 欧阳冬生 | 人参皂苷c-k与拉莫三嗪的组合物在制备抗癫痫药物中的应用 |
| CN106191300A (zh) * | 2016-09-22 | 2016-12-07 | 中南大学湘雅三医院 | 预测儿童患者严重药物性皮肤不良反应的生物标志物及应用 |
Non-Patent Citations (1)
| Title |
|---|
| 沈关心等: "现代免疫学实验技术", vol. 1, 31 October 1998, 武汉：湖北科学技术出版社, pages: 387 - 388 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588162A (zh) * | 2022-03-30 | 2022-06-07 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
| CN114588162B (zh) * | 2022-03-30 | 2023-10-27 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022084843A (ja) | 2022-06-07 |
| JP2021500083A (ja) | 2021-01-07 |
| SG11202003391XA (en) | 2020-05-28 |
| US20200318189A1 (en) | 2020-10-08 |
| WO2019080077A1 (zh) | 2019-05-02 |
| KR20200077555A (ko) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmad et al. | Clinical relevance of advances in genetics and pharmacogenetics of IBD | |
| Ban et al. | The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease | |
| Fellermann et al. | A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon | |
| EP3822367A1 (en) | Detection processes using sites of chromosome interaction | |
| Rosenbaum et al. | Hypothesis: sarcoidosis is a STAT1-mediated disease | |
| ES2671119T3 (es) | Métodos de análisis genéticos | |
| EP1924712B1 (en) | Methods for characterizing and treating cognitive impairment in aging and disease | |
| US10337004B2 (en) | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide | |
| Dey-Rao et al. | Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation | |
| RU2590691C2 (ru) | Прогноз кинетики вируса гепатита с при лечении, исключающем интерферон | |
| Gautier et al. | Kidney dysfunction in adult offspring exposed in utero to type 1 diabetes is associated with alterations in genome-wide DNA methylation | |
| US20140057903A1 (en) | Methods for characterizing and treating cognitive impairment in aging and disease | |
| Wong et al. | More than a drug target: Purinergic signalling as a source for diagnostic tools in epilepsy | |
| US20230279491A1 (en) | Treatments for a sub-population of inflammatory bowel disease patients | |
| CN111278990A (zh) | 评估抗癫痫药物拉莫三嗪引发皮肤药物不良反应风险的方法、其检测试剂和其用途 | |
| US20240034799A1 (en) | Methods and systems of stratifying inflammatory disease patients | |
| Liu et al. | Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease | |
| TWI827964B (zh) | 檢測磺胺衍生物之抗癲癇藥物引起的藥物過敏反應之方法及套組，以及套組之用途 | |
| TWI650423B (zh) | 評估抗癲癇藥物拉莫三嗪引發皮膚藥物不良反應風險的方法、其檢測試劑及其用途 | |
| CN114127310A (zh) | 评估表皮生长因子受体抑制剂引发皮肤药物不良反应风险的方法、其检测套组及其用途 | |
| Yang et al. | The emerging genetic diversity of hereditary spastic paraplegia in Korean patients | |
| TWI804620B (zh) | 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途 | |
| JP7101358B1 (ja) | 肝臓疾患の発症リスクの検出方法、及び肝臓疾患の発症リスク検出用キット | |
| TWI728427B (zh) | 評估表皮生長因子受體抑制劑引發皮膚藥物不良反應風險的方法、其檢測套組及其用途 | |
| Zhang et al. | Cluster analysis of genome-wide expression differences in disease-unaffected ileal mucosa in inflammatory bowel diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |